Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes

Diabetes and Vascular Disease Research

Volumn 10, Issue 6, 2013, Pages 483-488

  Tehrani, Sara ^a   Mobarrez, Fariborz ^a   Lins, Per Eric ^a   Adamson, Ulf ^a   Wallén, Håkan N ^a   Jörneskog, Gun ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

microcirculation; Statin; type 1 diabetes

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ATORVASTATIN; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN DERIVATIVE; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROPRUSSIDE SODIUM; PLACEBO; SHORT ACTING INSULIN; THROMBOMODULIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL MICROPARTICLE; FEMALE; FOREARM; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; LOW DRUG DOSE; MALE; MICROALBUMINURIA; MICROCIRCULATION; MICROVASCULATURE; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SKIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

MICROCIRCULATION; STATIN; TYPE 1 DIABETES;

ADMINISTRATION, CUTANEOUS; ADULT; BIOLOGICAL MARKERS; CELL-DERIVED MICROPARTICLES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IONTOPHORESIS; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MIDDLE AGED; PYRROLES; RISK FACTORS; SKIN; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84885965984     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113491275     Document Type: Article

References (28)

1. Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. Diabetes Res Clin Pract. 2005 ; 6852: 3-14
2. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004 ; 18: 805-815
3. Rendell M, Bamisedun O. Diabetic cutaneous microangiopathy. Am J Med. 1992 ; 93: 611-618
4. Skrha J, Prázný M, Haas T, et al. Comparison of laser-Doppler flowmetry with biochemical indicators of endothelial dysfunction related to early microangiopathy in Type 1 diabetic patients. J Diabetes Complications. 2001 ; 15: 234-240
5. Chang CH, Tsai RK, Wu WC, et al. Use of dynamic capillaroscopy for studying cutaneous microcirculation in patients with diabetes mellitus. Microvasc Res. 1997 ; 53: 121-127
6. Tur E, Yosipovitch G, Bar-On Y. Skin reactive hyperemia in diabetic patients. A study by laser Doppler flowmetry. Diabetes Care. 1991 ; 14: 958-962
7. Roustit M, Cracowski JL. Non-invasive assessment of skin microvascular function in humans: an insight into methods. Microcirculation. 2012 ; 19: 47-64
8. Khan F, Elhadd TA, Greene SA, et al. Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care. 2000 ; 23: 215-220
9. Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002 ; 51: 2840-2845
10. Tehrani S, Mobarrez F, Antovic A, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res. 2010 ; 126: e225 - e231
11. Jörneskog G, Kalani M, Kuhl J, et al. Early microvascular dysfunction in healthy normal weight males with heredity for type 2 diabetes. Diabetes Care. 2005 ; 28: 1495-1497
12. Mobarrez F, Egberg N, Antovic J, et al. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res. 2012 ; 129: 95-97
13. Fried LF, Forrest KY, Ellis D, et al. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications. 2001 ; 15: 113-119
14. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992 ; 35: 447-451
15. Zhang A, Vertommen J, Van Gaal L, et al. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract. 1995 ; 29: 189-194
16. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009 ; 54: 810-819
17. Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002 ; 56: 1-11
18. Holowatz LA, Thompson-Torgerson CS, Kenney WL. The human cutaneous circulation as a model of generalized microvascular function. J Appl Physiol. 2008 ; 105: 370-372
19. Holowatz LA, Kenney WL. Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans. J Physiol. 2011 ; 589: 4787-4797
20. Clough GF, L'Esperance V, Turzyniecka M, et al. Functional dilator capacity is independently associated with insulin sensitivity and age in central obesity and is not improved by high dose statin treatment. Microcirculation. 2011 ; 18: 74-84
21. Stulc T, Kasalová Z, Prázný M, et al. Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. Physiol Res. 2003 ; 52: 439-445
22. Forst T, Wilhelm B, Pfützner A, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res. 2008 ; 5: 298-303
23. Prázný M, Kasalová Z, Mazoch J, et al. Microvascular reactivity and endothelial function in type 2 diabetic patients with hyperlipidemia treated with simvastatin: 3-year follow-up. Prague Med Rep. 2009 ; 110: 290-300
24. Casey RG, Joyce M, Moore K, et al. Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes. Diab Vasc Dis Res. 2007 ; 4: 53-61
25. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010 ; 87: 98-107
26. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 ; 305: 2556-2564
27. Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis?. Curr Vasc Pharmacol. 2010 ; 8: 612-631
28. Serné EH, Stehouwer CD, ter Maaten JC, et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation. 1999 ; 99: 896-902